Niacin and Lovastatin Interaction

Drug interaction information between Niacin and Lovastatin.

Niacin and Lovastatin have a documented moderate interaction in FDA labeling.

FDA drug labeling documents a moderate-severity interaction between Niacin and Lovastatin. This page displays the available source-record category and label text. The category is not an individual risk estimate or medication-combination direction.

Drug A

Niacin

Vitamin B3 (Lipid-Modifying)

Drug B

Lovastatin

HMG-CoA Reductase Inhibitor (Statin)

How They Interact

Using niacin along with lovastatin increases the risk of serious muscle breakdown and pain.

FDA Label Information

Gemfibrozil Other fibrates Niacin (nicotinic acid) (≥ 1 g/day) Other Drug Interactions Cyclosporine The risk of myopathy/rhabdomyolysis is increased by concomitant administration of cyclosporine (see WARNINGS , Myopathy/Rhabdomyolysis ).

Frequently Asked Questions

What SPL severity band is on file for Niacin + Lovastatin?

Compiled FDA labeling labels this pair moderate. That is a source-record field, not an individual medication-combination decision.

Which drug in this pair has the larger labeled-interaction portfolio?

Lovastatin has 30 labeled pairs on file vs Niacin's 21. In the moderate band specifically: Niacin has 10 (also Atorvastatin, Ezetimibe, Ezetimibe/Simvastatin, Fluvastatin); Lovastatin has 17 (also Spironolactone, Ketoconazole, Verapamil, Cyclosporine).

What mechanism field is on file for Niacin and Lovastatin?

Using niacin along with lovastatin increases the risk of serious muscle breakdown and pain.

Lovastatin carries more major-labeled pairs than Niacin

SPL source-record counts only. This page's band is moderate · classes on file: Niacin (Vitamin B3 (Lipid-Modifying)); Lovastatin (HMG-CoA Reductase Inhibitor (Statin)).

Lovastatin has 2 major-labeled pairs vs Niacin's 0. This page itself is in the moderate band, not the major band.

Niacin

0 major · 10 moderate · 11 minor · 21 total

Lovastatin

2 major · 17 moderate · 11 minor · 30 total

Sources: FDA Drug Labels (SPL) via openFDA (2026). This is for informational purposes only and is not medical advice. This registry does not provide individual medication-combination directions.